Xultophy 100/3.6 is a prescription drug used to improve blood sugar levels in adults with type 2 diabetes. Learn about its dosages, how to take it, and more.

Xultophy 100/3.6, which improves blood sugar levels in adults with type 2 diabetes, can cause side effects. Learn what they are and how to manage them.

Xultophy 100/3.6 (insulin degludec and liraglutide; Novo Nordisk) injection is now available as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus ...

The FDA has approved Novo Nordisk’s Xultophy and Sanofi’s Soliqua on the same day, pitching the rival diabetes combination into head-to-head competition. Both products combine a long acting ...

COPENHAGEN, Denmark, Dec. 4, 2017 /PRNewswire/ -- New findings from an indirect comparison between Xultophy ® and IGlarLixi published in the Journal of Medical Economics show that treatment with ...

Xultophy is supplied as a solution for subcutaneous injection containing 100 Units/mL insulin degludec and 3.6mg/mL liraglutide. It is available as 3mL prefilled pens in 5-count cartons.

Xultophy ® is indicated in Canada as an adjunct to lifestyle modifications for the once-daily treatment of adults with type 2 diabetes mellitus to improve glycemic control in combination with ...

Diabetes drugmaker Novo Nordisk on Saturday presented findings from the DUAL IX study at the American Diabetes Association's 78th Scientific Sessions.

* Says Xultophy (IDegLira) demonstrates similar glucose control with reduced risk of hypoglycaemia and a superior weight profile compared to basal-bolus therapy * Says the trial successfully ...

Novo Nordisk is voluntarily recalling 1,468 product samples listed in the table below of Levemir®, Tresiba®, Fiasp®, Novolog® and Xultophy®, to the consumer level. These products are being ...

Analyses of DUAL(TM) trial data compared Xultophy(R) (IDegLira)to insulin degludec and liraglutide alone in both insulin-naïve and insulin-treated patients New analyses of phase 3a DUAL(TM ...